A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.
Andrew Hahn, MD
Andrew Hahn, MD, is a medical oncologist at MD Anderson Cancer Center.
Articles by Andrew Hahn, MD
Latest Updated Articles
Dr Hahn on the Phase 2 LenCabo Trial in RCCOctober 30th 2025